Sandoz Misses Sales Forecasts as Europe Supply Problems Weigh
Sandoz sales in the third quarter fell short of expectations on European supply constraints and a tough German market, Vontobel says.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Sales at the Swiss generic medicines maker Sandoz Group came in below expectations in the third quarter. Analyst Stefan Schneider of Vontobel says in a note that supply problems in Europe and a harder situation in Germany were behind the shortfall.
Stronger demand for biosimilar drugs created supply shortages in Europe and other international markets. The continued weakness in anti-infectives was expected, the analyst adds, and should fade.
Because of these factors, the company narrowed its full-year sales growth guidance to 5% to 6% at constant currency.
why it matters
Vontobel asks whether these problems are temporary or have already been resolved. For investors, the key question is whether sales momentum recovers in coming quarters, so the narrower guidance will be closely watched.
market impact
Sandoz shares: weaker sales and narrower guidance weigh on the stock
- Sandoz shares pressure down — sales missed expectations and full-year guidance was narrowed
tags
instruments
sources
- Sandoz Hit by Sales Shortfall Due to Europe Challenges — Market Talk, 28 October 2026 at 07:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗